Progress in etiology and internal medical treatment of nocturia in diabetic patients

doi:10.3877/cma.j.issn.2095-3216.2024.01.007

Abstract

Abstract:

As a common complication of diabetes, nocturia has complex etiology, high morbidity, and low cure rate, which affects the quality of life of diabetic patients and can increase mortality. In recent years, the combination of lifestyle adjustments, medication, and other internal medical treatment has yielded more positive results. This article reviewed the progress on the epidemiology, etiology, and internal medical treatment of nocturia complicated in diabetes.

Key words: Diabetes mellitus, Nocturia, Etiology, Treatment

Meng Wang, Ruimin Zhang, Bo Fu, Qian Wang, Zheyi Dong, Xiangmei Chen. Progress in etiology and internal medical treatment of nocturia in diabetic patients[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(01): 46-49.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2024.01.007

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2024/V13/I01/46

References 36

[1]	Wein AJ. Re: International Continence Society (ICS) report on the terminology for nocturia and nocturnal lower urinary tract function [J]. J Urol, 2019, 202(4): 665-666.
[2]	Weiss JP. Nocturia: "do the math" [J]. J Urol, 2006, 175(3 Pt 2): S16-S18.
[3]	Weiss JP, Blaivas JG, Bliwise DL, et al. The evaluation and treatment of nocturia: a consensus statement [J]. BJU Int, 2011, 108(1): 6-21.
[4]	Schneider T, de la Rosette JJ, Michel MC. Nocturia: a non-specific but important symptom of urological disease [J]. Int J Urol, 2009, 16(3): 249-256.
[5]	Choo MS, Ku JH, Park CH, et al. Prevalence of nocturia in a Korean population aged 40 to 89 years [J]. Neurourol Urodyn, 2008, 27(1): 60-64.
[6]	Liew LC, Tiong HY, Wong ML, et al. A population study of nocturia in Singapore [J]. BJU Int, 2006, 97(1): 109-112.
[7]	Fitzgerald MP, Litman HJ, Link CL, et al. The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the BACH survey [J]. J Urol, 2007, 177(4): 1385-1389.
[8]	Tikkinen KA, Auvinen A, Johnson TM 2nd, et al. A systematic evaluation of factors associated with nocturia--the population-based FINNO study [J]. Am J Epidemiol, 2009, 170(3): 361-368.
[9]	Fu Z, Wang F, Dang X, et al. The association between diabetes and nocturia: a systematic review and meta-analysis [J]. Front Public Health, 2022, 10: 924488.
[10]	Abrams P, Andersson KE, Apostolidis A, et al. 6th International Consultation on Incontinence. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence [J]. Neurourol Urodyn, 2018, 37(7): 2271-2272.
[11]	Van Kerrebroeck P, Andersson KE. Terminology, epidemiology, etiology, and pathophysiology of nocturia [J]. Neurourol Urodyn, 2014, 33(Suppl 1): S2-S5.
[12]	Gordon DJ, Emeruwa CJ, Weiss JP. Management strategies for nocturia [J]. Curr Urol Rep, 2019, 20(11): 75.
[13]	Gulur DM, Mevcha AM, Drake MJ. Nocturia as a manifestation of systemic disease [J]. BJU Int, 2011, 107(5): 702-713.
[14]	Brown JS, Wessells H, Chancellor MB, et al. Urologic complications of diabetes [J]. Diabetes Care, 2005, 28(1): 177-185.
[15]	Bansal R, Agarwal MM, Modi M, et al. Urodynamic profile of diabetic patients with lower urinary tract symptoms: association of diabetic cystopathy with autonomic and peripheral neuropathy [J]. Urology, 2011, 77(3): 699-705.
[16]	Victor RG, Li N, Blyler CA, et al. Nocturia as an unrecognized symptom of uncontrolled hypertension in black men aged 35 to 49 years [J]. J Am Heart Assoc, 2019, 8(5): e010794.
[17]	Cho MC, Ku JH, Paick JS. Alpha-blocker plus diuretic combination therapy as second-line treatment for nocturia in men with LUTS: a pilot study [J]. Urology, 2009, 73(3): 549-553.
[18]	Paschou SA, Bletsa E, Saltiki K, et al. Sleep apnea and cardiovascular risk in patients with prediabetes and type 2 diabetes [J]. Nutrients, 2022, 14(23)：4989.
[19]	Guilleminault C, Lin CM, Gonçalves MA, et al. A prospective study of nocturia and the quality of life of elderly patients with obstructive sleep apnea or sleep onset insomnia [J]. J Psychosom Res, 2004, 56(5): 511-515.
[20]	Andersson KE, Van Kerrebroeck P. Pharmacotherapy for nocturia [J]. Curr Urol Rep, 2018, 19(1): 8.
[21]	Suman S, Robinson D, Bhal N, et al. Management of nocturia: overcoming the challenges of nocturnal polyuria [J]. Br J Hosp Med (Lond), 2019, 80(9): 517-524.
[22]	Everaert K, Hervé F, Bosch R, et al. International Continence Society consensus on the diagnosis and treatment of nocturia [J]. Neurourol Urodyn, 2019, 38(2): 478-498.
[23]	Gravas S, Gacci M, Gratzke C, et al. Summary paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms [J]. Eur Urol, 2023, 84(2): 207-222.
[24]	Przydacz M, Chlosta M, Dudek P, et al. Desmopressin treatment for nocturia caused by nocturnal polyuria: practical guidelines [J]. Cent European J Urol, 2020, 73(4): 498-505.
[25]	Chung E. Desmopressin and nocturnal voiding dysfunction: clinical evidence and safety profile in the treatment of nocturia [J]. Expert Opin Pharmacother, 2018, 19(3): 291-298.
[26]	Weiss JP, Zinner NR, Klein BM, et al. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial [J]. Neurourol Urodyn, 2012, 31(4): 441-447.
[27]	Sand PK, Dmochowski RR, Reddy J, et al. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study [J]. J Urol, 2013, 190(3): 958-964.
[28]	Weiss JP, Herschorn S, Albei CD, et al. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study [J]. J Urol, 2013, 190(3): 965-972.
[29]	Yamaguchi O, Juul KV, Falahati A, et al. Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program [J]. Low Urin Tract Symptoms, 2020, 12(1): 8-19.
[30]	Suvada K, Plantinga L, Vaughan CP, et al. Comorbidities, age, and polypharmacy limit the use by US older adults with nocturia of the only FDA-approved drugs for the symptom [J]. Clin Ther, 2020, 42(12): e259-e274.
[31]	Kaminetsky J, Fein S, Dmochowski R, et al. Efficacy and safety of SER120 nasal spray in patients with nocturia: pooled analysis of 2 randomized, double-blind, placebo controlled, phase 3 trials [J]. J Urol, 2018, 200(3): 604-611.
[32]	Monaghan TF, Bliwise DL, Denys MA, et al. Phenotyping nocturnal polyuria: circadian and age-related variations in diuresis rate, free water clearance and sodium clearance [J]. Age Ageing, 2020, 49(3): 439-445.
[33]	Monaghan TF, Epstein MR, Bliwise DL, et al. Time of peak nocturnal diuresis rate between men with secondary nocturnal polyuria versus nocturnal polyuria syndrome [J]. Neurourol Urodyn, 2020, 39(2): 785-792.
[34]	Monaghan TF, Suss NR, Epstein MR, et al. Differential nocturnal diuresis rates among patients with and without nocturnal polyuria syndrome [J]. Eur Urol Focus, 2020, 6(2): 320-326.
[35]	Dani H, Esdaille A, Weiss JP. Nocturia: aetiology and treatment in adults [J]. Nat Rev Urol, 2016, 13(10): 573-583.
[36]	Wisniewski K, Qi S, Kraus J, et al. Discovery of potent, selective, and short-acting peptidic V2 receptor agonists [J]. J Med Chem, 2019, 62(10): 4991-5005.

Please choose a citation manager

Content to export